Here's Why Gilead Sciences Stock Surged 21% in a Month [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Much of this rally followed the Jan. 21 announcement that full results from the late-stage ASCENT-04/KEYNOTE-D19 study were published in The New England Journal of Medicine (“NEJM”). Image Source: Zacks Investment Research The phase III ASCENT-04 study is evaluating the combination of Gilead's oncology drug Trodelvy (sacituzumab govitecan-hziy) with Merck 's MRK blockbuster immuno-oncology drug Keytruda (pembrolizumab) in patients with previously untreated, inoperable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1. The study enrolled 443 patients across multiple study sites. This study met its primary endpoint of progression-free survival (PFS) with a 35% reduced risk of disease progression or death for Trodelvy plus Keytruda (n=221) combination as compared to Keytruda plus chemotherapy (n=222). Median PFS with Trodelvy plus Keytruda was 11.2 months versus 7.8 months when Keytruda was given in combination with chemotherapy. The
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck (MRK) Reports Q4 Earnings: What Key Metrics Have to Say [Yahoo! Finance]Yahoo! Finance
- Merck (MRK) Is Up 5.6% After Cautious 2026 Outlook And Ongoing Oncology Investment Plans – What's Changed [Yahoo! Finance]Yahoo! Finance
- Merck (MRK) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Merck and Pfizer decline vs the broader market as results released [Yahoo! Finance]Yahoo! Finance
- Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms [MSNBC.com]MSNBC.com
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 2/3/26 - Form 8-K
- 1/28/26 - Form 4
- 1/28/26 - Form 4
- MRK's page on the SEC website